Only two of seven triptan medicines available globally are publicly funded in New Zealand: sumatriptan and rizatriptan.
NOT BSTOTAL BS
NOT BS — Verdict: True
Verified by Lenz ·
The Short Version
Current New Zealand evidence supports the claim. PHARMAC’s schedule and decision records show that only sumatriptan and rizatriptan are publicly funded, while the other five triptan medicines used globally are not subsidised in New Zealand. Older sources about availability or approval do not rebut this, because they address access rather than public funding.
Caveats
Funding is formulation-specific: some sumatriptan products, such as the injection, are not funded even though sumatriptan tablets are.
The claim is time-sensitive; older New Zealand sources describe a different access landscape before PHARMAC’s 2022 decision.
Public funding is not the same as approval or availability for private purchase; some migraine medicines may still be obtainable without being subsidised.